A clinical trial update was recorded on October 2, 2026, for a study titled "TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis." The study is registered under identifier NCT06726577 and is listed as a Phase 1/Phase 2 trial. Its current status is RECRUITING, according to the ClinicalTrials.gov record.
The trial is evaluating TP04HN106 in patients with amyotrophic lateral sclerosis. No results have been posted for this study at this stage, and the record does not state efficacy or safety outcomes. The listing reflects the trial's current recruitment phase only.
Liraglutide is an approved compound, and this entry reflects a registered clinical trial record rather than new approval or labeling information. Details such as enrollment criteria, trial sites, and sponsor information are available through the official ClinicalTrials.gov listing linked in the source. As the study is still recruiting, no interim or final findings have been reported as of the date listed.
Readers interested in background on liraglutide, including its approved uses and general pharmacology, can consult the compound overview for additional context.